Blockade of CD28 or CD40LG, including but not limited to genetic or pharmacologic means, mAbs and chimeric antigen receptor-based therapy, will suppress tumor growth and BM infiltration, thereby offering a novel therapeutic approach for the treatment of T-ALL. The gene discussed is CD28; the disease is acute lymphoblastic leukemia.